

NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE

Interventional Procedures Advisory Committee

Minutes of the Committee's 171st meeting held at 10:30 on Thursday 12th July 2018 at NICE, 10 Spring Gardens, London, SW1A 2BU

PRESENT:

Dr Tom Clutton-Brock (Chair)
Mr Jonathan Anderson
Mrs Sally Brearley
Dr Chris Carroll
Dr Andrew Cook (Vice Chair)
Mr Mahmoud Elfar
Dr Anthony Emmerson
Mrs Rosemary Harris
Mr Colin Howie
Mr Alistair Jenkins
Dr Tim Kinnaird
Mr Malcolm Lowe-lauri
Dr Neil McGuire
Mr Kieran Murphy
Dr Peter Murphy
Mr Frank Smith
Dr Dhiraj Tripathi

In Attendance

NICE Staff:

Ms Ria Skelton - Senior Medical Editor
Mrs Helen Gallo- Analyst, IPP
Professor Kevin Harris - Programme Director Clinical Advisor, IPP
Mr Azad Hussain – Administrator, IPP
Miss Chloe Kastoryano - Public Involvement Adviser, PIP
Dr Ignacio Malagon – Consultant Clinical Advisor, IPP
Professor John Powell, Consultant Clinical Advisor, IPP
Mrs Vassilia Verdiel - Analyst IPP
Mrs Bijal Joshi, Programme Manager, IPP
Mark Campbell, Acting Programme Director, IPP

Observers:

Gunveer Plahe – Public Health Registrar
Lucie Collinson – Public Health Registrar

Specialist Advisors: Lise Sproson – Senior Research Associate for IP1033/2

Company representatives:

Vitalstim for IP1033/2
JS Group for IP697/2
Synergo Medical for 395/2
Boston Scientific for IP675/2
SIRTEX, Terumo and Quirem Medical BTG for IP1081/2

Apologies: Dr Zahida Adam
Dr Wael Agur
Dr Nicholas Chalmers
Mr Anthony Hatswell
Mr Tim Jackson
Dr James Tysome

Note: The order in which the Committee took items of business at the meeting might differ from the agenda

Meeting started: 10:33

Chris Carroll and Andrew Cook arrived at 10:56

Kieran Murphy arrived at 12:29

Introduction to the meeting

The Chairman welcomed the Committee Members and observers – specifically Lise Sproson as a specialist advisor. As well as Mark Campbell who is the new Acting Programme Director, Gunveer Plahe and Lucie Collinson who joined NICE recently as Public Health Registrars.

The Chair announced that Ignacio Malagon will be leaving NICE

The Chairman also welcomed the members of the public and company representatives present at the meeting.

Code of conduct for members of the public and company representatives attending the meeting

The Chairman outlined the code of conduct for the members of the public and company representatives attending the meeting.

1. Any Other Business

None

2. Minutes of previous meeting

Members accepted these as a correct record.

Rosemary Harris suggested we record which companies are present at the time of each topic discussion. The Committee agreed that this would be helpful to do.

3. Matters arising

None

4. Agenda changes

The chairman informed the Committee that the meeting run according to the agenda as no changes have to be made.

The order of the meeting will be as follows: IP1033/2, IP697/2, IP395/2, IP675/2, IP1081/2, IP1569, IP1704, and IP1237

5. NICE's Advisory Body guide to declaring a conflict of interest

The Chairman drew the Committee's attention to NICE's advisory body quick guide for declaring conflicts of interest.

6. Newly Notified Procedures

IP1033/2 Transcutaneous neuromuscular electrical stimulation for oropharyngeal dysphagia

The discussion on IP1033/2 Transcutaneous neuromuscular electrical stimulation for oropharyngeal dysphagia started at 10:45

Lise Sproson declared she had been involvement in research on this procedure and had published on this topic. She was not permitted to stay for the decision making

No conflicts of interest were declared for this procedure by IPAC.

The Committee was reminded that equalities issues was discussed at the brief stage.

Introduced by **Alistair Jenkins** and **Lise Sproson**

The Chairman declared a Part Two and members of the public as well as company representatives and Lise Sproson left the meeting at 11:17

The Committee made its provisional recommendations on the safety and efficacy of the procedure.

The discussion on IP1033/2 Transcutaneous neuromuscular electrical stimulation for oropharyngeal dysphagia ended at 11:44

The members of the public as well as company representatives returned at 11:57.

IP697/2 Electrically-stimulated intravesical chemotherapy for superficial bladder cancer

The discussion on IP697/2 Electrically-stimulated intravesical chemotherapy for superficial bladder cancer started at 11:58

No conflicts of interest were declared for this procedure

The Committee was reminded that equalities issues was discussed at the brief stage.

Introduced by **Dhiraj Tripathi** and **Mahmoud Elfar**

The Chairman declared a Part Two and members of the public as well as company representatives left the meeting at 12:29.

The Committee made its provisional recommendations on the safety and efficacy of the procedure.

The discussion on IP697/2 Electrically-stimulated intravesical chemotherapy for superficial bladder cancer ended at 12:51

The members of the public as well as company representatives returned at 13:20.

7. Public Consultation comments

IP395/2 Intravesical microwave hyperthermia and chemotherapy for superficial bladder cancer

The discussion on IP395/2 Intravesical microwave hyperthermia and chemotherapy for superficial bladder cancer started at 13:21

No conflicts of interest were declared for this procedure

The Committee was reminded that equalities issues was discussed at the brief stage.

Introduced by **Mahmoud Elfar**

The Committee considered the consultation comments and made changes to sections 3.6, 2.3, 3.9 in part 1.

The Chairman declared a Part Two and members of the public as well as company representatives left the meeting at 13:50

The Committee upheld its decision on the safety and efficacy of the procedure.

The discussion on IP395/2 Intravesical microwave hyperthermia and chemotherapy for superficial bladder cancer ended at 13:54

The company representatives returned to the meeting at 13:57.

IP675/2 Bronchial thermoplasty for severe asthma

The discussion on IP675/2 Bronchial thermoplasty for severe asthma started at 15:57

No conflicts of interest were declared for this procedure

The Committee was reminded that equalities issues was discussed at the brief stage.

Introduced by **Jon Anderson**

The Committee considered the consultation comments.

The Chairman declared a Part Two and company representatives left the meeting at 14:14

The Committee changed its decision on the safety and efficacy of the procedure from Special to Standard

The discussion on IP675/2 Bronchial thermoplasty for severe asthma ended at 14:32

The members of the public as well as company representatives returned to the meeting at 14:33

IP1081/2 Selective internal radiation therapy for unresectable primary intrahepatic cholangiocarcinoma

The discussion on IP1081/2 Selective internal radiation therapy for unresectable primary intrahepatic cholangiocarcinoma started at 14:33

No conflicts of interest were declared for this procedure

The Committee was reminded that equalities issues was discussed at the brief stage.

Introduced by **Tom Clutton-Brock**

The Committee considered the consultation comments and made changes to section 2.4

The Chairman declared a Part Two and members of the public as well as company representatives left the meeting at 15:06

The following study, identified during consultation, will be added to the main table of the Overview:

Shaker T M, Chung C, Varma M K et al. (2018) Is there a role for Yttrium-90 in the treatment of unresectable and metastatic intrahepatic cholangiocarcinoma?. American Journal of Surgery 215(3), 467-470.

The discussion on IP1081/2 Selective internal radiation therapy for unresectable primary intrahepatic cholangiocarcinoma ended at 15:26

The company representatives returned to the meeting at 15:26.

IP1569 Transurethral water jet ablation for lower urinary tract symptoms caused by benign prostatic hyperplasia

The discussion on IP1569 Transurethral water jet ablation for lower urinary tract symptoms caused by benign prostatic hyperplasia started at 15:27

No conflicts of interest were declared for this procedure

The Committee was reminded that equalities issues was discussed at the brief stage.

Introduced by **Mahmoud Elfar**

The Committee considered the consultation comments

The Chairman declared a Part Two and company representatives left the meeting at 15:37

The Committee upheld its decision on the safety and efficacy of the procedure.

The discussion on IP1569 Transurethral water jet ablation for lower urinary tract symptoms caused by benign prostatic hyperplasia ended at 15:42

The members of the public as well as company representatives returned to the meeting at 15:42.

8. Briefs of procedures for future assessment

IP1704 Collagen paste for closing an anal fistula

The discussion on IP1704 Collagen paste for closing an anal fistula started at 15:42

The Chair reminded the committee that the equalities and diversity section is in the brief and should be reviewed and commented on as necessary by all the Committee.

Introduced by **Tom Clutton-Brock**

Tom Clutton–Brock declared that he is a co-investigator for a grant received by his institution from the NIHR into treatments for anal fistula. This was considered a direct non-financial professional and personal interests and it was agreed that the vice chair of IPAC would take over for any future discussion on this topic and Tom Clutton-Brock would be excluded from the meeting.

The Committee advised on the content of the brief for evaluation of this procedure.

The discussion on IP1704 Collagen paste for closing an anal fistula ended at 15:47

IP1237 Percutaneous insertion of a cerebral protection device to prevent cerebral embolism during transcatheter aortic valve implantation

The discussion on IP1237 Percutaneous insertion of a cerebral protection device to prevent cerebral embolism during transcatheter aortic valve implantation started at 15:47

The Chair reminded the committee that the equalities and diversity section is in the brief and should be reviewed and commented on as necessary by all the Committee.

Introduced by **Tim Kinnaird**

The Committee advised on the content of the brief for evaluation of this procedure.

The discussion on IP1237 Percutaneous insertion of a cerebral protection device to prevent cerebral embolism during transcatheter aortic valve implantation ended at 15:54

9. Other meeting matters

None

10. Date of the next meeting

The **172nd** meeting of the Interventional Procedures Advisory Committee will be held on **Thursday 09 August 2018**, and will start promptly at 1030. The meeting will be held at **NICE, 10 Spring Gardens, London, SW1A 2BU**

The meeting ended at **15:54**